Can-Fite BioPharma Ltd. (CANF)
NYSEAMERICAN: CANF · Real-Time Price · USD
3.150
-0.130 (-3.96%)
Jul 31, 2026, 4:00 PM EDT - Market closed
Can-Fite BioPharma Employees
Can-Fite BioPharma had 5 employees as of December 31, 2025. The number of employees did not change compared to the previous year.
Employees
5
Change (1Y)
n/a
Growth (1Y)
n/a
Revenue / Employee
$81,000
Profits / Employee
-$1,965,600
Market Cap
7.21M
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 5 | 0 | - |
| Dec 31, 2024 | 5 | -3 | -37.50% |
| Dec 31, 2023 | 8 | 0 | - |
| Dec 31, 2022 | 8 | 0 | - |
| Dec 31, 2021 | 8 | 0 | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Bolt Biotherapeutics | 23 |
| Imunon | 20 |
| MetaVia | 8 |
| Aprea Therapeutics | 8 |
| AEON Biopharma | 8 |
| Traws Pharma | 7 |
| Adial Pharmaceuticals | 5 |
| XTL Biopharmaceuticals | 5 |
CANF News
- 12 days ago - Can-Fite Positive Phase 2a Pancreatic Cancer Study Data Accepted for Presentation at ESMO Congress 2026, One of the World's Premier Scientific Meetings in Oncology - GlobeNewsWire
- 18 days ago - Can-Fite BioPharma (CANF) Secures Patent for Cancer Treatment - GuruFocus
- 18 days ago - Can-Fite BioPharma secures Australian Patent Office allowance for namodenoson - TheFly
- 18 days ago - Can-Fite Secures Australian Patent Allowance Supporting Namodenoson Development and Marketing in Liver and Pancreatic Cancer - GlobeNewsWire
- 26 days ago - Can-Fite BioPharma (CANF) Completes Patient Enrollment for Psoriasis Study - GuruFocus
- 26 days ago - Can-Fite BioPharma enrolls 247 patients in Piclidenoson trial - TheFly
- 26 days ago - Can-Fite Achieves Key Pivotal Phase 3 Psoriasis Milestone with Completion of Patient Enrolment for the Interim Analysis: Data Expected Q4 2026/Q1 2027 - GlobeNewsWire
- 4 weeks ago - CANF Reiterated by HC Wainwright & Co. -- Price Target Raised to $8 - GuruFocus